TY - CHAP
T1 - Myeloproliferative neoplasms
T2 - Thrombophilic clonal stem cell diseases
AU - Tefferi, Ayalew
PY - 2009
Y1 - 2009
N2 - Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are currently classified as BCR-ABL-negative classic myeloproliferative neoplasms (MPN). According to the revised 2008 World Health Organization (WHO) classification system, adult chronic myeloid neoplasms are now divided into four broad categories; myelodysplastic syndrome (MDS), MPN, "MDS/MPN overlap" and "myeloid or lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1" [1]. The WHO MPN category includes the four classic MPN: chronic myelogenous leukemia (CML; BCR-ABL-positive), PV, ET, and PMF. All three BCR-ABL-negative MPN are uncommon and incidence figures are estimated at 0.2-2.5/100,000 for ET [2-4], 0.4 to 1.5/100,000 for PMF [2, 3] and 0.8-2.6/100,000 for PV [5, 6]. The median age at diagnosis for all these three MPN is approximately 60∈years [7].
AB - Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are currently classified as BCR-ABL-negative classic myeloproliferative neoplasms (MPN). According to the revised 2008 World Health Organization (WHO) classification system, adult chronic myeloid neoplasms are now divided into four broad categories; myelodysplastic syndrome (MDS), MPN, "MDS/MPN overlap" and "myeloid or lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1" [1]. The WHO MPN category includes the four classic MPN: chronic myelogenous leukemia (CML; BCR-ABL-positive), PV, ET, and PMF. All three BCR-ABL-negative MPN are uncommon and incidence figures are estimated at 0.2-2.5/100,000 for ET [2-4], 0.4 to 1.5/100,000 for PMF [2, 3] and 0.8-2.6/100,000 for PV [5, 6]. The median age at diagnosis for all these three MPN is approximately 60∈years [7].
UR - http://www.scopus.com/inward/record.url?scp=77950546440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950546440&partnerID=8YFLogxK
U2 - 10.1007/978-0-387-79962-9_10
DO - 10.1007/978-0-387-79962-9_10
M3 - Chapter
C2 - 19377924
AN - SCOPUS:77950546440
SN - 9780387799612
T3 - Cancer Treatment and Research
SP - 157
EP - 179
BT - Coagulation in Cancer
ER -